Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Epistem Announces Opening of US Laboratory

Published: Thursday, March 06, 2014
Last Updated: Thursday, March 06, 2014
Bookmark and Share
Laboratory will support the expansion of Epistem's contract research division.

Epistem Holdings Plc has announced that it has opened a US laboratory based in Baltimore, Maryland. The laboratory will support the expansion of Epistem's contract research division within the US.

The US laboratory is currently offering histology and immunohistochemistry (IHC) services to a range of US clients, expanding upon the success of the GcLP and GLP compliant UK laboratory.

The experienced and skilled technical team have already developed IHC protocols for a panel of over 150 antibodies which are available to clients worldwide.

Epistem Co-Founder and Director of the Contract Services Business, Dr Catherine Booth commented "Epistem's specialist contract research services provide valuable support to drug discovery and development pipelines. We already have strong relationships with both companies, academic and government groups on the East Coast along with a US Business team based in Boston and Baltimore. We are excited to now be providing services locally to support this growing US business".


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Epistem Announces Further Partnership With The University of Manchester
Partnership will allow the Company to expand its existing range of wound healing models.
Tuesday, April 22, 2014
Epistem Announces Evaluation of Genedrive® for Pathogen Detection
Epistem in cooperative agreement with the US Air Force and with Johns Hopkins University.
Thursday, January 16, 2014
Epistem Presents GenetRx™ Clinical Data from Two Recently Completed Studies
Data presented on the use of scalp hair to assess androgen receptor directed therapies and to identify novel pharmacodynamic markers for an antisense molecule.
Thursday, November 12, 2009
Epistem Presents Further Data Supporting its Plucked Hair Biomarker Technology
Data on the effects of Gemcitabine on epithelial tissue released at the Institute of Cancer Research Centenary Conference.
Thursday, June 11, 2009
Epistem to Present Erlotinib Biomarker Data at AACR Meeting
Epistem plc will present results from its recently completed preclinical plucked hair biomarker study.
Wednesday, April 15, 2009
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!